Manufacturing company Nordson (NASDAQ:NDSN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 10.3% year on year to $817.7 million. The company’s full-year revenue guidance of $3.06 billion at the midpoint came in 2.4% above analysts’ estimates. Its non-GAAP profit of $3.25 per share was 5% above analysts’ consensus estimates.
Is now the time to buy NDSN? Find out in our full research report (it’s free for active Edge members).
Nordson (NDSN) Q2 CY2026 Highlights:
- Revenue: $817.7 million vs analyst estimates of $780.2 million (10.3% year-on-year growth, 4.8% beat)
- Adjusted EPS: $3.25 vs analyst estimates of $3.09 (5% beat)
- Adjusted EBITDA: $262.5 million vs analyst estimates of $254.2 million (32.1% margin, 3.3% beat)
- The company lifted its revenue guidance for the full year to $3.06 billion at the midpoint from $2.97 billion, a 2.9% increase
- Management raised its full-year Adjusted EPS guidance to $11.90 at the midpoint, a 3% increase
- Operating Margin: 27.3%, up from 25.3% in the same quarter last year
StockStory’s Take
Nordson’s second quarter results drew a strong positive market reaction, fueled by broad-based sales gains across all major business segments. Management pointed to particularly robust growth in the Advanced Technology and Medical segments, highlighting accelerated order momentum and a 35% year-over-year increase in backlog. CEO Sundaram Nagarajan emphasized the impact of the company’s Ascend Strategy and operational execution, stating, “We are winning due to our unique competitive advantages and the successful execution of our Ascend Strategy.” These factors led to record sales and profit performance, underpinned by strong cash conversion and margin expansion.
Looking ahead, Nordson’s raised full-year outlook is anchored by sustained strength in semiconductor and electronics demand, as well as continued normalization and growth in medical components. Nagarajan noted that the company’s backlog and order pipeline provide confidence for the remainder of the year and into 2027, with additional upside potential as North American chip manufacturing projects ramp up. CFO Dan Hopgood added that the company’s balanced portfolio and disciplined capital allocation “provide significant firepower to strategically deploy capital, including acquiring strategic assets.”
Key Insights from Management’s Remarks
Management attributed the quarter’s outperformance to accelerated demand in Advanced Technology, stable growth in Medical and Fluid Solutions, and operational leverage across the business.
- Advanced Technology momentum: The Advanced Technology Solutions segment achieved all-time record sales, with both Electronics Dispense and Test & Inspection product lines benefiting from strong semiconductor and broad electronics demand. Management highlighted that growth in this segment was well above long-term targets, reflecting the peak of a favorable market cycle.
- Medical and Fluid Solutions acceleration: Sales in Medical and Fluid Solutions set a new quarterly record, with broad-based growth in engineered fluid and medical product lines. Order outlook remains strong, especially in medical components and interventional products, positioning the segment for continued above-trend expansion.
- Industrial Precision steady performance: The Industrial Precision Solutions segment delivered stable organic growth, driven by packaging, industrial coatings, and plastics processing demand. While growth rates were more modest relative to other segments, management emphasized the segment’s consistency and role as a core earnings contributor.
- Operational execution drives margins: Margin improvement was attributed to volume leverage and disciplined cost control, especially in high-growth segments. Hopgood noted that ongoing operational initiatives under the NBS Next framework are enhancing efficiency and supporting best-in-class margins across the portfolio.
- M&A and capital allocation discipline: With leverage down to 1.7x and strong cash generation, management reiterated its commitment to pursuing both bolt-on and platform acquisitions, particularly in medical and test & inspection. The company remains focused on opportunities that meet strict strategic and financial criteria, while continuing to invest in organic growth.
Drivers of Future Performance
Nordson expects continued growth to be driven by demand in advanced electronics, medical components, and disciplined capital deployment, though management noted mixed trends by segment.
- Semiconductor and electronics demand: Management expects ongoing strength in semiconductor and electronics, particularly in Asia, to sustain order backlog and revenue into next year. Nagarajan highlighted additional upside potential as North American chip infrastructure investments begin to translate into orders, which has not yet been reflected in current results.
- Medical market normalization: Sales in medical components and interventional products are expected to stabilize at mid-single-digit growth rates, supported by normalized demand and strong order pipelines. Hopgood noted that some segments are returning to typical growth, while others are still ramping toward historical trends, suggesting a more balanced outlook for the Medical and Fluid Solutions division.
- Margin stability and inflation risks: Management anticipates maintaining strong margins through operational excellence, but flagged ongoing inflationary pressures tied to tariffs, freight, and commodities as risks. Hopgood emphasized that while tariffs themselves do not have a significant direct impact, the broader inflationary environment remains an area of active management.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team will be tracking (1) the pace and sustainability of order momentum in Advanced Technology Solutions, (2) normalization and growth trends within Medical and Fluid Solutions, and (3) evidence of operational improvements driving margin expansion across segments. The timing and scope of new chip manufacturing investments in North America could serve as a key incremental growth lever.
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.